201 related articles for article (PubMed ID: 9723249)
1. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method.
First MR; Weiskittel P; Burton M; Shah M; Dreyer D; Fleck P; Bey C; Peddi R; Canafax D; Schroeder TJ
Transplant Proc; 1998 Aug; 30(5):1701-5. PubMed ID: 9723249
[No Abstract] [Full Text] [Related]
2. Conversion from cyclosporine Sandimmune to cyclosporine Neoral in the stable renal transplant population.
Griffin PJ; Moore RH; Jurewicz WA; Lord RH; Webley Y; Jenkins J
Transplant Proc; 1997; 29(1-2):303. PubMed ID: 9123007
[No Abstract] [Full Text] [Related]
3. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method.
First MR; Weiskittel P; Shah M; Peddi VR; Canafax D; Schroeder TJ
Transplant Proc; 1998 Dec; 30(8):3955-7. PubMed ID: 9865260
[No Abstract] [Full Text] [Related]
4. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.
Tsang WK; Ho YW; Tong KL; Chan WH; Chan A
Transplant Proc; 1996 Jun; 28(3):1330-2. PubMed ID: 8658681
[No Abstract] [Full Text] [Related]
5. Converting renal transplant patients maintained on Sandimmune to a new microemulsion formulation, Sandimmune Neoral.
Chu SH; Pang ST; Chiang YJ; Chuang CK; Chen HW; Chen CS; Chou CC; Huang CC
Transplant Proc; 1998 Nov; 30(7):3521-3. PubMed ID: 9838543
[No Abstract] [Full Text] [Related]
6. Conversion from Sandimmune to Neoral in renal transplant: functional histopathological, and pharmacokinetic changes.
Roessler E; Herrera S; Espinoza M; Ayala A; Reynolds E; González F; Espinoza O; Undurraga A; Muñoz R; Arcos O; Galaz G
Transplant Proc; 1998 Aug; 30(5):1756-7. PubMed ID: 9723268
[No Abstract] [Full Text] [Related]
7. Estimation of mean relative bioavailability of cyclosporine Sandimmune and Neoral using NONMEM in renal transplant recipients.
Lee KL; Lee KT; Chung HM; Lin YP
Transplant Proc; 1998 Nov; 30(7):3526-9. PubMed ID: 9838545
[No Abstract] [Full Text] [Related]
8. Experience with clinical use of Sandimmun Neoral in renal transplant patients.
Min ZL; Zhao M; Zhu YH; Qi J; Wang LM; Wang YW
Transplant Proc; 1996 Jun; 28(3):1356-7. PubMed ID: 8658692
[No Abstract] [Full Text] [Related]
9. Effect of conversion from Sandimmune to Neoral on glomerular filtration rate in stable renal transplant recipients.
Steinmuller D; Dougherty J; Coutee J; Surek D; Swies G; Lewis R
Transplant Proc; 1997; 29(1-2):298-9. PubMed ID: 9123005
[No Abstract] [Full Text] [Related]
10. Conversion to cyclosporine microemulsion (Neoral) in stable renal transplant patients: results from a single center.
Cossu M; Satta R; Branca GF; Pala PG; Serra G; Satta RP; Sorba G
Transplant Proc; 1998 Aug; 30(5):1762-3. PubMed ID: 9723271
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients.
Gaspari F; Anedda MF; Signorini O; Amuchastegui SC; Perico N; Remuzzi G
Transplant Proc; 1998 Aug; 30(5):1654-5. PubMed ID: 9723229
[No Abstract] [Full Text] [Related]
12. Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients.
Hoyer PF; Boekenkamp A; Vester U; Offner G; Brodehl J
Transplant Proc; 1996 Aug; 28(4):2259-61. PubMed ID: 8769218
[No Abstract] [Full Text] [Related]
13. Time-dependent difference of the 12-hour trough levels of cyclosporine in renal transplant recipients with sandimmune capsule.
To H; Haba T; Uchida K; Fujimura A; Kobayashi E
Transplant Proc; 2000 Feb; 32(1):221-2. PubMed ID: 10701028
[No Abstract] [Full Text] [Related]
14. Measurement of lymphocyte cyclosporine levels in transplant patients.
Masri MA; Barbari A; Stephan A; Rizk S; Kilany H; Kamel G
Transplant Proc; 1998 Nov; 30(7):3561-2. PubMed ID: 9838559
[No Abstract] [Full Text] [Related]
15. Comparative study of population pharmacokinetics upon switching of cyclosporine formulation from Sandimmune to Neoral in stable renal transplant patients.
Yoshida K; Kimura T; Hamada Y; Saito T; Endo T; Baba S; Shimada S
Transplant Proc; 2001; 33(7-8):3146-7. PubMed ID: 11750351
[No Abstract] [Full Text] [Related]
16. Pharmacokinetic and safety evaluation of SangCya vs Neoral or Sandimmune in stable renal transplant recipients.
Gaston R; Alloway RR; Gaber AO; Rossi SJ; Schroeder TJ; Irish WD; Canafax DM; First MR
Transplant Proc; 1999; 31(1-2):326-7. PubMed ID: 10083128
[No Abstract] [Full Text] [Related]
17. Conversion from Sandimmune to Neoral in renal transplant recipients: two-year experience.
Wilczek HE; Akesson P; Warholm C
Transplant Proc; 1998 Aug; 30(5):1753-5. PubMed ID: 9723267
[No Abstract] [Full Text] [Related]
18. A two-year study of the new cyclosporine formulation Consupren in de novo renal transplant patients.
Stephan AG; Barbari A; Masri M; Kamel G; Barakat Khoury W; Karam A; Mokhbat J; Kilany H
Transplant Proc; 1998 Nov; 30(7):3563-4. PubMed ID: 9838560
[No Abstract] [Full Text] [Related]
19. Safety and efficacy of conversion from once daily Sandimmun to twice daily Neoral cyclosporine in renal allograft recipients.
Vathsala A; Lee WT; Lu YM; Woo KT
Transplant Proc; 1998 Aug; 30(5):1746-8. PubMed ID: 9723264
[No Abstract] [Full Text] [Related]
20. Neoral (cyclosporine) C2 monitoring in renal transplant recipients: a single-center experience in Asia.
Wong HS; Morad Z
Transplant Proc; 2003 Feb; 35(1):230-1. PubMed ID: 12591376
[No Abstract] [Full Text] [Related]
[Next] [New Search]
